The role of interleukin 23 in colitis-associated and spontaneous colon cancer

suppressive Treg effect also coincided with significantly greater IL-10 release. In contrast, Tregs from mice treated with Novobiocin, displayed similar suppressive function to their vehicle counterparts. While it is reasonable that inhibition of a pro-inflammatory cytokine or induction of an anti-inflammatory cytokine would have similar net consequences, the implications for the possible use of either of these two HSP90 inhibitors in tailored therapy for IBD patients remains an exciting one. Furthermore, as we increase our understanding of the anti-inflammatory mechanisms of HSP90 inhibition in murine models of IBD, this data will provide proof of principle for the expansion of current clinical trials using HSP90 inhibitors for cancer chemotherapy to include indications in IBD. Funding from K08DK080189 (EDZ) & CCFA-2652 (CBC) and UL1 RR025780 (EDZ & CBC) P-192.